Prior to joining Novo Nordisk Dr Schindler was Vice President, head
of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD
iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research
at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various
leadership roles at Boehringer Ingelheim, Germany after having started
his career with Glaxo Wellcome/GSK, UK in 1997. Dr Schindler holds a
PhD from the University of Cambridge, UK.